Investor

Morgan Cheatham, partner and head of healthcare and life sciences at Breyer Capital, provides highlights of the venture capital firm's strategy when funding emerging technologies and the risks associated with backing these innovations.

Alexandre Momeni, a partner at General Catalyst, describes how the VC firm funds visionary founders building frontier technologies while balancing high-risk bets with responsible innovation and strategic portfolio construction.

The company will grow its clinical team and expand its offerings across GI partner clinics representing 700 physicians, after an 800% rise in patient volume.

Jayme Strauss, chief commercial and clinical officer at Precision Neuroscience, joined MobiHealthNews to discuss the company's brain-computer interface aimed at allowing individuals to control digital devices using their thoughts.

The company will use the funds to support a 510(k) submission to the FDA for its Flexi-Port SLF-TANL for oncology patients.

The company plans to offer an aggregate of 7.9 million shares of its common stock with an initial public offering price between $18 and $20 per share.

The company's computer vision technology tracks supply and implant usage in hospital operating and procedural rooms.

Marcel Botha, cofounder and CEO of 10XBeta, warns that President Trump's tariffs may jeopardize the quality and safety of medical innovations and hinder patient care.

Indian e-clinic startup CureBay also looks to expand its rural network.

The funds will be used to help the company expand into the employer and health plan markets and speed up the development of its AI technology for providers and members.